Hernández-Juárez J, Moreno-Hernández M, Ricardo-Moreno T, García-González A, García-Latorre EA, Hernández-López JR, Ramírez-San Juan E, Alvarado-Moreno A, Isordia-Salas I, Majluf-Cruz A

Language: Spanish
References: 27
Page: 252-260
PDF size: 149.11 Kb.

ABSTRACT

Introduction. During the fluid phase of hemostasis, fibrinogen is converted into fibrin, but other hemostatic factors are required. Reference values of hemostatic factors are established by manufacturers producing reagents using individuals with a specific genetic background. Objective. To establish reference values for hemostatic factors in the Mexican indigenous and Mestizo populations. Material and methods. We carried out a cross-sectional, descriptive study of healthy adult Mexicans. Clotting activity was evaluated using coagulometric assays. Blood donors were informed about the nature of the study and informed consent was obtained prior to blood being drawn. The protocol was approved by the Ethics Committee of our institution. Results. One hundred and twenty samples were assayed (60 females and 60 males). Fibrinogen was higher in mestizos and in females. Reference values for factor XII ranged from 40-170% in indigenous subjects and from 36-159% in mestizos. Factor VIII ranged from 57-160% in indigenous subjects and from 51-209% in mestizo subjects. Reference values for the other hemostatic factors were also clearly different from the commercial reference values. Reference values for hemostatic factors in the Mexican population are different from traditionally used commercial reference values. There were significant differences between indigenous and mestizo Mexicans in the concentration of hemostatic factors with a tendency among mestizos to have higher factor concentrations. Low levels of plasma factor XII are frequent and perhaps may represent a risk factor for thrombotic events. Using these reference values may individualize the reposition of factors in Mexican hemophiliac patients.

REFERENCES

1. Mateen FJ, Shuaib A. Progress in clinical neurosciences: the antiplatelet agents and the role of the endothelium. Can J Neurol Sci 2007; 34: 270-9.

2. Ho G, Broze GJ Jr, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue pathway inhibitor-coagulation factor Xa complexes. J Biol Chem 1997; 272: 16838-44.

3. Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977; 74: 3903-07.

4. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.

5. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52.

6. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992; 29: 170-6.

7. Furie B, Furie BC. Molecular and cell biology of blood coagulation. N Engl J Med 1992; 326: 800-06.

8. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.

9. Jackson DP. Hereditary disorders of blood coagulation due to defective and deficient synthesis of protein. Trans Am Clin Climatol Assoc 1971; 82: 114-23.

10. Ratnoff OD. Hereditary disorder of blood coagulation. Deficient synthesis versus defective synthesis. J Chronic Dis 1971; 24: 79-81.

11. Hyatt HW Sr. Hemophilia and conditions producing hemorrhagic diatheses simulating hemophilia. A review. J Natl Med Assoc 1963; 55: 394-400.

12. Majluf-Cruz A, Moreno-Hernandez M, Ruiz-de-Chavez- Ochoa A, Monroy-García R, Majluf-Cruz K, Guardado-Mendoza R, et al. Activated protein C resistance and factor V Leiden in Mexico. Clin Appl Thromb Hemost 2008; 14: 428-37.

13. Lisker R, Ramirez E, Babinsky V. Genetic structure of autochtonous populations of Meso-America: Mexico. Hum Biol 1996; 68: 395-404.

14. Zacharski R, Rosenstein R. Standardization of the one stage assay for factor VIII (antihemophilic factor). Am J Clin Pathol 1978; 70: 280-6.

15. Clinical and Laboratory Standards Institute. 2008. Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory. Ed. 3 Approved Guideline, CSLI/NCCLS Document C28-A3.

16. Vargas-Alarcón G, Hernández-Pacheco G, Zuñiga J, Rodríguez- Pérez JM, Pérez-Hernández M, Rangel C, Villarreal-Garza C, et al. Distribution of HLA-B alleles in Mexican Amerindian populations. Immunogenetics 2003; 54: 756-60.

17. Cook DG, Cappuccio FP, Atkinson RW, Wicks PD, Chitolie A, Nakandakare ER, Sagnella GA, et al. Ethnic differences in fibrinogen levels: the role of environmental factors and the betafibrinogen gene. Am J Epidemiol 2001; 153: 799-806.

18. Iso H, Folsom AR, Wu KK, Finch A, Munger RG, Sato S, Shimamoto T, et al. Hemostatic variables in Japanese and Caucasian men. Plasma fibrinogen, factor VIIc, factor VIIIc, and von Willebrand factor and their relations to cardiovascular disease risk factors. Am J Epidemiol 1989; 130: 925-34.

19. Lutsey PL, Cushman M, Steffen LM. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 2006; 4: 2629-35.

20. Lutsey PL, Wassel CL, Cushman M, Sale MM, Divers J, Folsom AR. Genetic admixture is associated with plasma hemostatic factor levels in self-identified African Americans and Hispanics: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost 2012; 10: 543-9.

21. Majluf-Cruz A, Moreno-Hernandez M, Martinez-Esquivel N, Ruiz de Chávez-Ochoa AA, Coria-Ramírez E, Monroy-García R, Vela-Ojeda J, et al. Factor VIII activity among young Mexi260 Hernández-Juárez J, et al. Valores de referencia para los factores hemostáticos. Rev Invest Clin 2014; 66 (3): 252-260 can patients with acute myocardial infarction. Gac Med Mex 2008; 144: 199-206.

22. Bank I, Libourel EJ, Middeldorp S, Hamulyák K, van Pampus EC, Koopman MM, Prins MH, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.

23. Kraaijenhagen RA, Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.

24. O’Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-3.

25. Madan R, Gupt B, Saluja S, Kansra UC, Tripathi BK, Guliani BP. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India 2010; 58: 481-4.

26. Colman RW. Are hemostasis and thrombosis two sides of the same coin? J Exp Med 2006; 20; 203: 493-5.

27. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007; 5: 1143-8.